Medical Oncology: Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 intro 4T1-Luc orthotropic implants reduces primary tumor and metastatic pulmonary lesions

On August 24, 2021   /   Home Page, Publications  

Drug Delivery and Translational Research: Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies

On November 10, 2020   /   Home Page, Publications  

Gynecologic Oncology Reports: Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer surgery

On September 17, 2020   /   Home Page, Publications  

Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer surgery

Investigational New Drugs: Intratumoral Submicron Particle Docetaxel Inhibits Syngeneic Renca Renal Cancer Growth & Increases CD4+, CD8+ and Treg Levels in Peripheral Blood

On April 3, 2020   /   Home Page, Publications  

Investigational New Drugs: Intratumoral submicron particle docetaxel inhibits syngeneic Renca renal cancer growth and increases CD4+, CD8+, and Treg levels in peripheral blood

Journal of Aerosol Medicine and Pulmonary Drug Delivery: Inhaled Submicron Particle Paclitaxel (NanoPac®) Induces Tumor Regression and Immune Cell Infiltration in an Orthotopic Athymic Nude Rat Model of Non-Small Cell Lung Cancer

On August 1, 2019   /   Home Page, Publications  

Inhaled Submicron Particle Paclitaxel (NanoPac®) Induces Tumor Regression and Immune Cell Infiltration in an Orthotopic Athymic Nude Rat Model of Non-Small Cell Lung Cancer

Cancers 2019: Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts

On May 3, 2019   /   Publications  

Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts

Journal of Aerosol Medicine and Pulmonary Drug Delivery: Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac®) in a Rodent Model

On October 29, 2018   /   Publications  

Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac®) in a Rodent Model

Cancer Chemotherapy & Pharmacology: Phase I study of intraperitoneal nanoparticulate paclitaxel (nanotax®) in patients with peritoneal malignancies

On August 9, 2017   /   Publications  

Phase I study of intraperitoneal nanoparticulate paclitaxel (nanotax®) in patients with peritoneal malignancies